Publications + Posters

 |  AACR Molecular Cancer Therapeutics

May 2025

CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Katherine Lazarides, et al.

 |  AACR Molecular Cancer Therapeutics

May 2025

Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency

Antoine Simoneau, et al.

 |  Bioorganic & Medicinal Chemistry Letters

April 2025

Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor

Scott Throner, et al.

 |  AACR

April 2025

TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors with MTAP loss

Kimberly J. Briggs, et al.

 |  AACR

April 2025

Genetic and pharmacological disruption of the HBS1L/PELO complex impairs mRNA homeostasis and leads to in vivo tumor regressions in FOCAD-deleted cancers

Lauren Martires, et al.